Free Trial
OTCMKTS:BAYRY

Bayer Aktiengesellschaft 8/6/2025 Earnings Report

Bayer Aktiengesellschaft logo
$8.22 +0.08 (+0.98%)
As of 08/29/2025 03:59 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.35
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.42 billion
Expected Revenue
$10.79 billion
Beat/Miss
Beat by +$1.63 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY), founded in 1863 and headquartered in Leverkusen, Germany, is a global life sciences company with core competencies in healthcare and agriculture. Over its 160-year history, Bayer has evolved from a regional chemical producer into one of the world’s leading innovators in pharmaceuticals, consumer health products and crop science. The company’s mission emphasizes advancing health and nutrition for people and animals, underpinned by ongoing investment in research and development.

In the pharmaceutical segment, Bayer develops and markets prescription medicines in areas such as cardiology, women’s health, hematology, oncology and ophthalmology. Its consumer health division offers well-known over-the-counter remedies for everyday ailments, ranging from pain management to allergy relief, supported by strong global brands. Following the 2018 acquisition of Monsanto, Bayer’s crop science business spans seeds and traits, crop protection solutions and digital farming tools, providing integrated offerings to farmers in major agricultural markets worldwide.

Bayer maintains a broad international footprint, serving customers across Europe, the Americas, Asia-Pacific and emerging markets. The company operates research facilities in Germany, the United States and other key innovation hubs, collaborating with academic institutions and industry partners to advance new therapies and sustainable agricultural practices. Bayer’s leadership team is headed by CEO Bill Anderson, whose tenure focuses on driving operational excellence, enhancing the product pipeline and strengthening the company’s sustainability commitments.

View Bayer Aktiengesellschaft Profile

More Earnings Resources from MarketBeat